ReviewPharmacoEconomics2017

Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Benjamin Kearns et al.PubMed ↗Publisher ↗

No numbers read from the abstract.